Supernus Pharmaceuticals, Inc.
Clinical trials sponsored by Supernus Pharmaceuticals, Inc., explained in plain language.
A pharmaceutical company specializing in central nervous system (CNS) treatments, including epilepsy and ADHD.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- ADHD drug SPN-812 tested for Long-Term safety in children Results expected Sep 2026 (estimated)
- New depression pill shows promise in Mid-Stage trial Results expected Dec 2026 (estimated)
- Parkinson's pump study tracks Real-Life symptom control Results expected Aug 2027 (estimated)
- New drug SPN-817 aims to tame Hard-to-Control seizures Results expected Aug 2027 (estimated)
-
ADHD drug SPN-812 tested for Long-Term safety in children
Disease control OngoingThis study investigates the long-term safety and effectiveness of SPN-812 (viloxazine) in children and adolescents with ADHD. Participants who completed a prior SPN-812 study can continue taking the medication once daily for up to 72 months. The trial includes children aged 4–17 …
Phase 3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for deadly seizures: experimental drug SAGE-547 tested
Disease control Expanded access (ended)This study offered SAGE-547, an experimental drug given as a continuous IV infusion, to people aged 6 months and older with super-refractory status epilepticus—a dangerous condition where seizures continue despite standard treatments. The goal was to see if the drug could help co…
Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:59 UTC
-
New drug ZULRESSO offers hope for moms with postpartum depression
Symptom relief ApprovedThis program provides early access to ZULRESSO (brexanolone) for adult women with postpartum depression before the drug is widely available. Eligible women receive a one-time injection under medical supervision. The goal is to help ease severe depression symptoms quickly.
Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 17:07 UTC